Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

BACKGROUND AND PURPOSE: We investigated plasma neurofilament light chain concentration (pNfL) as a biomarker for neuroaxonal damage and disease activity using data from Phase 3 trials of ozanimod in relapsing multiple sclerosis (RMS). METHODS: pNfL was measured before and after ozanimod 0.46 mg or 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Sarah, Comi, Giancarlo, Cree, Bruce A. C., Arnold, Douglas L., Steinman, Lawrence, Sheffield, James K., Southworth, Harry, Kappos, Ludwig, Cohen, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291872/
https://www.ncbi.nlm.nih.gov/pubmed/34292643
http://dx.doi.org/10.1111/ene.15009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291872/
https://www.ncbi.nlm.nih.gov/pubmed/34292643
http://dx.doi.org/10.1111/ene.15009

Ejemplares similares